Transducible peptide therapy for uveal melanoma and retinoblastoma

Archives of Ophthalmology

Volumn 120, Issue 10, 2002, Pages 1341-1346

  Harbour, J William ^a,b   Worley, Lori ^a   Ma, Duanduan ^a   Cohen, Michael ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PEPTIDE ANTIBODY; PROTEIN ANTIBODY; PROTEIN BCL 2; PROTEIN BCL 2 ANTIBODY; PROTEIN HDM2 ANTIBODY; PROTEIN MDM2; PROTEIN P53; TYROSYLGLYCYLARGINYLLYSYLLYSYLARGINYLARGINYLGLUTAMYLARGINYLARGINYLARGINYLGL YCINAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL KILLING; CELL SURVIVAL; CELL TRANSFORMATION; CELL VIABILITY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NICK END LABELING; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; RABBIT; RETINA INJURY; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TISSUE REPAIR; TUMOR CELL CULTURE; TUMOR REGRESSION; UVEA MELANOMA; WESTERN BLOTTING; XENOGRAFT;

EID: 0036822698     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.120.10.1341     Document Type: Article

References (23)

1. Harbour JW, Murray TG. Management of intraocular tumors. In: Albert D, ed. Ophthalmic Surgery: Principles and Techniques. Malden, Mass: Blackwell Publishers; 1998:682-705.
2. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126-1132.
3. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157:1795-1801.
4. Coupland SE, Anastassiou G, Stang A, et al. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol. 2000;191:120-126.
5. Kishore K, Ghazvini S, Char DH, Kroll S, Selle J. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol. 1996;121:561-567.
6. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997;7:860-869.
7. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
8. Chana JS, Wilson GD, Cree IA, et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol. 1999;83:110-114.
9. Jay V, Yi Q, Hunter WS, Zielenska M. Expression of Bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med. 1996;120:497-498.
10. Wang JL, Zhang ZJ, Choksi S, et al. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000;60:1498-1502.
11. Kondo Y, Kondo S, Liu J, Haqqi T, Barnett GH, Barna BP. Involvement of p53 and WAF1/CIP1 in gamma-irradiation-induced apoptosis of retinoblastoma cells. Exp Cell Res. 1997;236:51-56.
12. Nork TM, Poulsen GL, Millecchia LL, Jantz RG, Nickells RW. p53 Regulates apoptosis in human retinoblastoma. Arch Ophthalmol. 1997;115:213-219.
13. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999;96:4325-4329.
14. Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman KG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol. 1999;19:3395-3402.
15. Nagahara H, Vocero-Akbani AM, Snyder EL, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med. 1998;4:1449-1452.
16. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126.
17. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948-953.
18. Chene P, Fuchs J, Bohn J, Garcia-Echeverria C, Furet P, Fabbro D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol. 2000;299:245-253.
19. Florenes VA, Oyjord T, Holm R, et al. TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer. 1994;69:253-259.
20. Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000;407:645-648.
21. D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A, Soddu S. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting. J Gene Med. 2000;2:11-21.
22. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569-1572.
23. Chan HS, DeBoer G, Thorner PS, Haddad G, Gallie BL, Ling V. Multidrug resistance: clinical opportunities in diagnosis and circumvention. Hematol Oncol Clin North Am. 1994;8:383-410.